Bone Biologics Corp Warrants
BBLGW
5 hedge funds and large institutions have $62K invested in Bone Biologics Corp Warrants in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 5 → 5 (0)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
54% less capital invested
Capital invested by funds: $134K → $62K (-$72K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$939 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$1.64K |
BBLGW Hedge Fund Activity: Q2 2022 in Review
5 of the 5,960 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics Corp Warrants (BBLGW) for Q2 2022, worth a combined $62K — down 54% from $134K a quarter earlier.
Fund positioning in BBLGW was balanced in Q2 2022: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 1 trimmed.
The largest buyer was Clear Street, adding an estimated $939. The largest seller was UBS Group, cutting an estimated $1.64K.
- 5 institutional investors held Bone Biologics Corp Warrants (BBLGW) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $62K of Bone Biologics Corp Warrants stock for Q2 2022, down 54% quarter-over-quarter.
- 0 funds opened new Bone Biologics Corp Warrants positions in Q2 2022 and 0 closed out.
- The largest Bone Biologics Corp Warrants buyer in Q2 2022 was Clear Street, an estimated $939 added.
- The largest Bone Biologics Corp Warrants seller in Q2 2022 was UBS Group, an estimated $1.64K sold.
Based on aggregated 13F filings for Q2 2022.